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Purpose: In breast cancer patients who do not undergo surgery 
due to metastatic disease or severe medical comorbidities, the 
unresected primary tumour may cause symptoms such as pain, 
skin ulceration and bleeding. Hypofractionated partial breast 
irradiation (HPBI) is a treatment modality aimed at achieving 
local control (LC) and reducing symptom burden while 
minimizing the duration of radiation treatments 
Methods and Materials: This retrospective review included all 
patients treated with HPBI for unresected breast tumours at a 
large tertiary cancer centre between August 2013 and December 
2015. Primary outcome measures were LC (no progression of 
disease after treatment) and feasibility (no discontinuation of 
HPBI due to acute toxicity). Secondary outcomes included: 
response (categorized as complete, > 50%, or < 50%), change in 
symptoms, and acute toxicities. 
Results: Twenty patients (22 breast tumours) were evaluated. 
Median age was 83 (range: 46-100). Thirteen of 22 (59%) breast 
tumours were ER/PR positive and 60% of patients had prior 
endocrine therapy for a median duration of 10 months (range: 1-
40). Eleven patients had comorbidities precluding surgery, seven 
had metastatic disease, and two declined surgery. Eleven 
patients (55%) presented with skin ulceration, four (20%) with 
substantial bleeding requiring dressing changes, and six (30%) 
with pain not adequately controlled with analgesics. Average 
size of the primary lesion was 6.1 cm (range: 2-14). HPBI was 
delivered as 5 fractions given once or twice per week; the 
prescribed dose was 35-40 Gy to the primary lesion, 25-35 Gy to 
the axilla, and 25 Gy to the supraclavicular fossa/whole breast, 
as indicated. Eighteen (90%) patients completed HPBI and 2 
stopped after 1 fraction (though not due to toxicity). Acute 
Grade 1 (RTOG scale) skin toxicity was seen in 12 patients and 
Grade 2 or 3 toxicity with moist desquamation in seven patients 
(no Grade 4 toxicities). Average follow up was 6.4 months (range: 
1-23). At three months follow up (n = 19), all had LC, with 16% 
having a complete response (CR), 37% a > 50% response, and 47% 
a < 50% response. Bleeding resolved in all and skin ulceration had 
a CR in 22% and partial response in 78%. At one year follow up (n 
= 10), nine had LC and one had progression (this patient declined 
completing HPBI after 1 fraction). CR was seen in 30%, > 50% 
response in 40%, and < 50% response in 10%. Skin ulceration had 
a CR in all five patients with documentation at this time point. 
One patient had 23 months follow up and had LC with complete 
resolution of symptoms. 
Conclusions: HPBI is a feasible treatment modality for LABC and 
is effective at achieving LC and reducing symptoms in the 
context of patients with metastatic disease or comorbidities 
precluding surgery. Longer follow up and prospective research is 
needed to further assess this approach. 
 
208 
DEFINING A HIGH-RISK GROUP IN PATIENTS RECEIVING 
HYPOFRACTIONATED BREAST RADIOTHERAPY FOR DCIS  
David Tiberi1, Michael Yassa1, Tarek Hijal2, Bernard Fortin1, 
Andrew J. Oar3, Mei Ling Yap4, Toni Vu1, Philip Wong1 
1Université de Montréal, Montréal, QC 
2McGill University, Montréal, QC 
3Western Sydney University, Campbelltown, New South Wales, 
Australia 
4University of South Wales, Liverpool, Australia 
 
Purpose: Conventionally fractionated adjuvant radiation therapy 
(RT) for invasive breast carcinomas and ductal carcinoma in situ 
(DCIS), has resulted in 10-year local recurrence rates of less than 
10%. Although the oncologic outcomes using hypofractionated RT 
(HF) for early invasive breast carcinoma is equivalent to 
conventional fractionation, there is no randomized trial 
published in the context of DCIS. This study aims at examining 
the Disease-Free Survival (DFS) of DCIS following HF in order to 
identify a population at high-risk (five-year DFS < 90%) of 
recurrence. 
Methods and Materials: Women with DCIS that were treated with 
surgery and HF at 3 Canadian and 2 Australian tertiary RT 
departments were identified. The median dose of HF was 42.5 
Gy (31.2-46.0) in 2.5-2.66 Gy per fraction. Treatment and 
outcomes were assessed through administrative databases and 
validated by chart review. Kaplan-Meier was used to estimate 
the DFS. Univariate and multivariate analyses were performed to 
examine the association between various pathological and 
treatment related factors and DFS. Competing risk analysis and 
Gray’s test were performed to determine the association of 
various risk factors with breast related events. 
Results: There were 600 women identified. Boost RT was 
administered to 224 (37.3%) patients. The median age was 66 
(42-86) years old. The median tumour size was 0.90 cm (0.1-6.3). 
Grade 3 DCIS was found in 30.6%. Surgical margins were ≤ 3 mm 
or positive in 35.8% and 3.8%, respectively. ER status was positive 
in 85.0% and adjuvant hormonal therapy was given to 57.5% of 
the patients. The median follow up was 5.4 years (0.2-11.5). The 
five-year DFS of all patients was 92.1%. On univariate analysis, 
tumour size, ER status, presence of tumour necrosis, and use of 
adjuvant hormonal therapy were not correlated with a worsened 
DFS. Grade 3 tumours and positive surgical margins were 
significantly (p < 0.0001 and p = 0.006) associated with shorter 
DFS. There were too few patients of age < 45 (n = 8) or with HER2 
known status (n = 62) for analysis. On multivariate analysis, 
Grade 3 (versus Grade 1-2 HR = 2.53 (95% Confidence Interval 
(CI): 1.46-4.36), p = 0.0009) and positive margins (versus 
negative HR = 3.05 (95%CI: 1.30-7.19), p = 0.0106) significantly 
worsened DFS, with five-year DFS of 87.9% and 78.0% 
respectively. Competing risk analysis suggested that there was a 
trend (p = 0.09) for positive surgical margins to be associated 
with increased breast related events. Grade 3 DCIS significantly 
(p = 0.0004) recurred more often than Grade 1-2 tumours. 
Conclusions: DCIS patients who received HF had DFS that is 
comparable to published results from conventional RT. Patients 
who have positive surgical margins and Grade 3 tumours are at 
higher risk of breast events after HF. Our future work will include 
a retrospective non-inferiority assessment of the efficacy of HF 
versus conventional RT in high-risk DCIS patients from the same 
institutions. 
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Purpose: To assess acute toxicities and clinical outcomes of 
craniospinal irradiation (CSI) delivered using Helical 
Tomotherapy (HT).  
Methods and Materials: We conducted a retrospective review of 
patients treated with HT CSI at the McGill University Health 
Centre between 2007 and 2015. In total, 45 patients with varying 
primary diagnoses including 22 (49%) with medulloblastoma, 
were analyzed. Median age was 18 years (3-46). Median CSI dose 
was 36 Gy (12-39.6) in 20 fractions (6-22), in both children and 
adults. A boost to the tumour bed or posterior fossa to a median 
dose of 19.8 Gy (6-32.4) was given in 80% of patients. Eighty-
three percent of patients received chemotherapy, with regimens 
varying according to histology. Kaplan-Meier curves were used 
for estimation of progression-free survival (PFS) and overall 
survival (OS). 
Results: Median follow up was 21 months (1-97). Ninety-five 
percent of children versus 71% of adults received chemotherapy 
(p = 0.03). There was a 24% (-5-47%), 53% (range = -124-87%), and 
69% (-55-94%) decrease in white blood cells, haemoglobin and 
platelets at nadir compared to baseline, with no statistically 
significant difference between children and adults. In total, 27% 
of pediatric patients and 25% of adults developed Grade ≥ 3 
cytopenia. Grade ≥ 1 nausea/vomiting occurred in 45% of 
children and 58% of young adults (p > 0.1); and Grade ≥ 2 
anorexia occurred in 27% and 13%, respectively. Mean percent 
weight loss over CSI course was 6% in children and 4% in adults. 
Four patients (9%) required nutritional support with nasogastric 
or percutaneous endoscopic gastrostomy tubes. Mean dose to the 
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thyroid, oesophagus, heart, lungs and kidneys was respectively 
15 Gy (9-23), 17 Gy (4-24), 8 Gy (2-13), 7 Gy (1-18) and 6 Gy (1-
12). Lung volume receiving 5 Gy (V5) was 50% (13-65%) and V20 
was 0 % (0-8%). For the entire cohort, two-year PFS and OS were 
75% and 93%, respectively. 
Conclusions: This large series confirms that HT CSI can achieve 
favourable clinical outcomes along with acceptable acute 
toxicities associated with low doses to organs at risk.  
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Purpose: The management of elderly patients with glioblastoma 
multiforme is evolving. Recent evidence suggests a treatment 
approach based on tumour molecular markers may improve 
outcomes in this population. Provincial guidelines were last 
updated in 2012. This report aimed to generate updated 
recommendations and provide the basis for provincial guideline 
development.  
Methods and Materials: The MEDLINE, EMBASE, PubMed and 
Cochrane databases were systematically searched for clinical 
trials published between January 2005 and January 2016 
evaluating treatment outcomes for elderly patients with 
glioblastoma.  
Results: Elderly is commonly defined as ≥ 65 years of age 
although definitions vary. Randomized controlled trials have 
compared different radiotherapy (RT) regimens, RT versus best 
supportive care alone, and different single-modality therapies 
(temozolomide [TMZ] versus RT) including subgroup analyses 
based on tumour MGMT promoter methylation status. Results 
from an international Phase III trial comparing combination 
RT/TMZ to RT alone are anticipated for release in the near 
future. 
Conclusions: 1) Elderly patients with Karnofsky Performance 
Status (KPS) ≥ 70 including those > 70 years of age should be 
offered RT in addition to best supportive care alone; 2) patients 
aged 65 years and older with KPS ≥ 70 may be considered for 
chemoradiotherapy. This guideline will be revisited following 
publication of the EORTC (26981-22981)/NCIC CTG (CE.3) trial; 
3) patients aged 65 years and older with KPS < 70, or with KPS > 
70% and wishing to avoid potential toxicities of combination 
therapy, may be offered single modality therapy. Patients should 
be tested for tumour MGMT promoter methylation. Those with 
methylated MGMT should be offered TMZ while those with non-
methylated MGMT should be offered RT. The alternate therapy 
may be offered at time of tumour progression; 4) The course of 
RT may be abbreviated to 40 Gy in 15 fractions in patients ≥ 60 
years of age, and to 25 Gy in 5 fractions in patients who are 
elderly (age ≥ 65 years and KPS 80 to 100%), frail (age ≥ 50 years 
and KPS of 50 to 70%) and elderly and frail (age ≥ 65 years and 
KPS of 50 to 70%). 
Based on these findings, a provincial working group will be 
formed to update current practice guidelines for the 
management of elderly patients with glioblastoma in Alberta. 
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Purpose:  Improvements in systemic therapy and diagnostic 
imaging are resulting in an increasing number of patients 
presenting with limited intracranial metastases. The optimal 
management of these patients is an area of active research. We 
aimed to establish a clinical practice guideline based on the best 
available evidence for the management of adult patients with 1-
3 brain metastases. 
Methods and Materials:  The MEDLINE, EMBASE, PubMed and 
Cochrane databases were systematically searched for clinical 
trials published between 2000 and 2015 evaluating treatment 
outcomes in patients ≥ 18 years of age with 1-3 brain metastases. 
Guideline recommendations were drafted and circulated to the 
Provincial CNS Tumour Team and a consensus survey was 
conducted. The recommendations were reviewed at the 2015 
Provincial CNS Tumour Team meeting and a guideline document 
was drafted and circulated to tumour team members and key 
stakeholders to achieve consensus. 
Results:  Prognostic scoring systems such as the recursive 
partitioning analysis (RPA) classification for brain metastases can 
aid in decision-making between more and less aggressive 
therapies. A favourable prognostic group includes patients with 
a Karnofsky Performance Score (KPS) ≥ 70, three or fewer 
cerebral metastases, and no progressive systemic disease. 
Patients with a favourable prognosis can be treated with multiple 
modalities, including: surgery, stereotactic radiosurgery (SRS), 
and/or whole brain radiation therapy (WBRT). Three randomized 
trials have compared outcomes in patients treated with surgery 
and WBRT compared to WBRT alone. Randomized trials have also 
investigated SRS with WBRT versus WBRT alone, and definitive 
therapy (SRS or Surgery) with versus without WBRT. Surgery and 
SRS have not been directly compared in a randomized trial. The 
methods for achieving group consensus on the drafted guidelines 
will be presented and discussed. 
Conclusions:  1) For patients with a single large symptomatic 
metastasis that is surgically accessible, total resection is 
recommended. SRS to the tumour bed and/or WBRT can be used 
to decrease the post-operative risk of recurrence; 2) SRS is an 
effective treatment for brain metastases less than 3 cm in 
diameter and especially in surgically inaccessible locations or 
patients who are not surgical candidates;  3) WBRT can be 
combined with surgery or SRS to increase local and regional 
disease control, but it may increase the likelihood of cognitive 
side effects without increasing overall survival; 4) 
Multidisciplinary discussions should be ongoing in regards to 
surveillance, imaging, and the use of options for initial and 
salvage treatment that balance cranial disease control and 
functional outcome. Patients are encouraged to participate in 
clinical trials. 
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Purpose:  Microsurgery and radiation treatment (RT) are 
therapeutic options for vestibular schwannomas (VS). Our 
purpose was to examine long-term outcomes in a geographically 
defined population of patients. 
Methods and Materials:  This is a population-based, 
retrospective review of 342 patients treated for VS between 
2002-2009, having a potential minimum follow up of five years. 
Patient management was routinely chosen after discussion in a 
provincial multidisciplinary conference. The primary endpoint 
was local control and the secondary endpoint was treatment-
related toxicity. Serviceable hearing (SH) was measured using 
the Gardner-Robertson scale and facial nerve dysfunction (FND) 
using the House-Brackmann (HB) grading. Progression free 
survival (PFS) was estimated using the Kaplan-Meier method. 
Serious adverse events (SAEs) were graded using the Common 
Terminology Criteria for Adverse Events (Version 4.03). 
